Compare MLEC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | IGC |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 31.2M |
| IPO Year | N/A | N/A |
| Metric | MLEC | IGC |
|---|---|---|
| Price | $0.22 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 162.7K | ★ 935.5K |
| Earning Date | 01-30-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,106,000.00 |
| Revenue This Year | $20.42 | $3.54 |
| Revenue Next Year | $30.00 | $15.12 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.36 | N/A |
| 52 Week Low | $0.21 | $0.25 |
| 52 Week High | $8.00 | $0.50 |
| Indicator | MLEC | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 20.34 | 39.57 |
| Support Level | $0.21 | $0.29 |
| Resistance Level | $0.34 | $0.36 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.61 | 25.36 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.